Capricor Therapeutics review

The short version

Capricor is a small company with one important drug. Deramiocel is a cell therapy for Duchenne muscular dystrophy, an inherited disease that destroys the muscles of boys and young men. The FDA rejected it in July 2025, Capricor ran a new Phase 3 trial, and an answer is now due on 22 November 2026. With a market value of under $500 million, the company’s future depends on it.

The latest FDA decision: delayed

On 24 August 2026 the FDA moved its decision from 22 August to 22 November, after accepting 24-month follow-up data and new analyses (BioSpace). The delay followed a bad month: on 29 July an expert panel voted 9 to 3 that the evidence did not show the drug works for the heart problems of Duchenne (AJMC). Capricor then asked the FDA to focus on arm and hand function instead. The shares rose about 32% around the news, as our FDA Decision Calendar shows, because investors had feared a rejection.

What it makes

Deramiocel is made from cells taken from donated hearts. It is given by infusion every three months and is thought to reduce inflammation and scarring rather than replace the missing protein. In the HOPE-3 Phase 3 trial, published in The Lancet, patients kept more arm and hand function than on placebo (p=0.029), which was the main goal. The heart result was weaker: after a statistical error was corrected, it went from p=0.04 to p=0.09, which is no longer statistically certain (Capricor Q2 2026 results).

Is it really new?

Yes. There is no approved cell therapy for Duchenne, and few treatments target arm function and the heart, which matter most in later stages of the disease. The question is not whether it is new but whether it works well enough.

The competition

Most patients take steroids. Newer options include Agamree (a gentler steroid), Duvyzat and Sarepta’s gene therapy Elevidys, which had serious safety problems in 2025. Those problems left families looking for safer treatments, which is why patient groups strongly support deramiocel. A positive decision would make it an add-on to these drugs rather than a replacement.

Money

Capricor held $237.9 million of cash on 30 June 2026, down from $318.1 million at the end of 2025, and lost $40.7 million in Q2. It says that lasts at least 12 months. An approval could bring a priority review voucher, which such companies usually sell for a large sum. It is also in a dispute with Nippon Shinyaku over who sells the drug in the US. Capricor says the pricing terms do not work and wants the agreement cancelled, and it expects arbitration to begin this fall.

Risks

• Rejection. After a first rejection and a negative panel, a second “no” would be very damaging. The shares could fall heavily in a day.
• Fragile data. Panel members described the evidence as fragile and raised concerns about the trial’s statistics.
• Sales rights. Even if approved, the dispute with Nippon Shinyaku could delay the launch.
• Share sales. Small companies often raise money after a decision, which dilutes shareholders.

Our take

The shares have swung between about $3 and $40 in the past year, and now trade around $7–8. That tells you how uncertain this is. Families badly want more options and the main trial was positive, but the FDA’s own experts were not convinced. Treat this as a binary event, not an investment case, and only with money you can afford to lose.